Business Wire

OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine

In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo ®. CoVepiT: a prophylactic vaccine against COVID-19, developed using ...
Business Wire

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

PARIS & NANTES, France--(BUSINESS WIRE)--Regulatory News: Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a French ...